Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Complement System01:27

Complement System

2.5K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
2.5K
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

18
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
18
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

48
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
48
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

59
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
59
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

71
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
71
Humoral Immune Responses01:36

Humoral Immune Responses

73.7K
Overview
73.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of acute metabolic decompensation in maple syrup urine disease: guidance based on international clinical practice.

Orphanet journal of rare diseases·2026
Same author

Association of Complement Genetics with Outcomes in IgA Nephropathy.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Normalization of nCounter Gene Expression Data Alters Molecular Diagnostics in Kidney Transplantation.

Journal of the American Society of Nephrology : JASN·2026
Same author

Adoptive γδ T cell therapy controls cytomegalovirus infection in preclinical transplantation models.

Nature communications·2026
Same author

Impaired thymic function is independently associated with an increased risk of posttransplant infections in kidney recipients.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

Shiga Toxin-Producing <i>Escherichia coli-</i>Associated Hemolytic Uremic Syndrome in Adult Kidney Transplant Recipients.

Kidney international reports·2025
Same journal

Luspatercept Induces Significant Improvement in Anemia in Dominant Thalassemia Secondary to Heterozygous STEAP3 and Beta-Thalassemia Trait.

American journal of hematology·2026
Same journal

POEMS Syndrome: 2026 Update on Diagnosis, Risk-Stratification, and Management.

American journal of hematology·2026
Same journal

EIF2AK1 As a Key Genetic Determinant of Luspatercept Resistance in Transfusion-Dependent Thalassemia.

American journal of hematology·2026
Same journal

Subtotal Versus Total Splenectomy in Children With Sickle Cell Disease: Clinical Outcomes and Splenic Function Assessed by Pocked Red Blood Cell Count.

American journal of hematology·2026
Same journal

High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1.

American journal of hematology·2026
Same journal

Peripheral Blood Lymphocytosis Reflecting an Underlying Thymoma.

American journal of hematology·2026
See all related articles

Related Experiment Video

Updated: Aug 13, 2025

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

30.7K

Complement-driven hemolytic uremic syndrome.

Juliette Leon1,2,3,4, Marie-Bénédicte LeStang1,4, Rebecca Sberro-Soussan1,4

  • 1Department of Kidney and Metabolic Diseases, Transplantation and Clinical Immunology, Necker Hospital, AP-HP, Paris, France.

American Journal of Hematology
|January 23, 2023
PubMed
Summary
This summary is machine-generated.

Complement alternative pathway overactivation drives atypical hemolytic uremic syndrome (aHUS). C5 blockade therapy significantly improved aHUS management, but its efficacy in secondary HUS requires further clinical trials.

More Related Videos

Depletion of Specific Cell Populations by Complement Depletion
06:17

Depletion of Specific Cell Populations by Complement Depletion

Published on: February 5, 2010

22.3K
Measuring the 50% Haemolytic Complement CH50 Activity of Serum
08:26

Measuring the 50% Haemolytic Complement CH50 Activity of Serum

Published on: March 29, 2010

38.0K

Related Experiment Videos

Last Updated: Aug 13, 2025

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

30.7K
Depletion of Specific Cell Populations by Complement Depletion
06:17

Depletion of Specific Cell Populations by Complement Depletion

Published on: February 5, 2010

22.3K
Measuring the 50% Haemolytic Complement CH50 Activity of Serum
08:26

Measuring the 50% Haemolytic Complement CH50 Activity of Serum

Published on: March 29, 2010

38.0K

Area of Science:

  • Nephrology
  • Immunology
  • Hematology

Background:

  • Primary atypical hemolytic uremic syndrome (aHUS) pathogenesis is driven by complement alternative pathway overactivation.
  • Complement dysregulation is common in aHUS, pregnancy-related HUS, and severe hypertension-associated HUS.
  • The role of complement activation in other HUS forms remains unclear.

Purpose of the Study:

  • To investigate the role of complement alternative pathway in HUS pathogenesis.
  • To evaluate the efficacy of C5 blockade therapy in different HUS subtypes.
  • To highlight the need for novel biomarkers and clinical trials.

Main Methods:

  • Review of current literature on complement alternative pathway in HUS.
  • Analysis of C5 blockade therapy outcomes in aHUS and secondary HUS.
  • Discussion of biomarker development and clinical trial design.

Main Results:

  • C5 blockade therapy has revolutionized aHUS management, reducing dialysis dependence.
  • Efficacy of C5 blockade in secondary HUS forms is less established, based on limited data.
  • Novel biomarkers are being developed to confirm complement-driven HUS.

Conclusions:

  • Complement alternative pathway dysregulation is central to aHUS.
  • C5 blockade is effective for aHUS but requires further investigation for secondary HUS.
  • Risk of meningococcal infection with C5 inhibition necessitates prophylaxis; treatment should be individualized.